Gotowa bibliografia na temat „Second-line therapy”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Second-line therapy”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Second-line therapy"
Murphy, Richard A., Henry Sunpath, Carmen Castilla, et al. "Second-Line Antiretroviral Therapy." JAIDS Journal of Acquired Immune Deficiency Syndromes 61, no. 2 (2012): 158–63. http://dx.doi.org/10.1097/qai.0b013e3182615ad1.
Pełny tekst źródłaCalmy, Alexandra, Fernando Pascual, and Nathan Ford. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 329. http://dx.doi.org/10.1016/s0140-6736(04)16716-0.
Pełny tekst źródłaKulwichit, Wanla. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 329–30. http://dx.doi.org/10.1016/s0140-6736(04)16717-2.
Pełny tekst źródłaCarr, Andrew. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 330. http://dx.doi.org/10.1016/s0140-6736(04)16718-4.
Pełny tekst źródłaWeiss, Jared M., and Thomas E. Stinchcombe. "Second‐Line Therapy for Advanced NSCLC." Oncologist 18, no. 8 (2013): 947–53. http://dx.doi.org/10.1634/theoncologist.2013-0096.
Pełny tekst źródłaBrandt, Kenneth D. "Second-line drug therapy for osteoarthritis." Clinical Medicine 1, no. 2 (2001): 110–12. http://dx.doi.org/10.7861/clinmedicine.1-2-110.
Pełny tekst źródłaMartin, Mike G., Ramaswamy Govindan, and Daniel Morgensztern. "Second-line therapy for esophageal cancer." Expert Review of Anticancer Therapy 7, no. 6 (2007): 871–76. http://dx.doi.org/10.1586/14737140.7.6.871.
Pełny tekst źródłaHamers, Raph L. "Dolutegravir for second-line antiretroviral therapy." Lancet Infectious Diseases 19, no. 3 (2019): 218–19. http://dx.doi.org/10.1016/s1473-3099(19)30035-0.
Pełny tekst źródłaAhmed, Mili, Douma Rabiâa, Jarrar Emna, et al. "Second-Line Therapy in Multiple Sclerosis." Multiple Sclerosis and Related Disorders 37 (January 2020): 101586. http://dx.doi.org/10.1016/j.msard.2019.11.061.
Pełny tekst źródłaBachner, Mark, and Maria De Santis. "Second-line therapy in bladder cancer." Current Opinion in Urology 19, no. 5 (2009): 533–39. http://dx.doi.org/10.1097/mou.0b013e32832eb473.
Pełny tekst źródłaRozprawy doktorskie na temat "Second-line therapy"
Mhangwane, Shushu Rirhandzu Comfort. "Predicting early and late first-line antiretroviral therapy virologic failure, and switch to second-line therapy in a military population in South Africa." Diss., University of Pretoria, 2018. http://hdl.handle.net/2263/64177.
Pełny tekst źródłaCourt, Richard Gray. "Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy." Master's thesis, University of Cape Town, 2015. http://hdl.handle.net/11427/13801.
Pełny tekst źródłaMgosha, Peter Charles. "Barriers to Switching Patients to Second-Line Antiretroviral Treatment Among Clinicians in Tanzania." ScholarWorks, 2017. https://scholarworks.waldenu.edu/dissertations/3535.
Pełny tekst źródłaJohnstone, Victoria. "Second-line antiretroviral therapy in a South African treatment programme : exploring determinants of switching and treatment outcomes." Thesis, London School of Hygiene and Tropical Medicine (University of London), 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.590631.
Pełny tekst źródłaNamukanja, Phoebe Monalisa-Mayambala. "Adverse effects on second-line highly active antiretroviral therapy (HAART) among HIV infected adults and children treated at Mildway Uganda." Thesis, University of Limpopo (Medunsa Campus), 2011. http://hdl.handle.net/10386/532.
Pełny tekst źródłaChen, Mei Hui. "A systematic review of the blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension." Thesis, University of British Columbia, 2009. http://hdl.handle.net/2429/12393.
Pełny tekst źródłaMeßner, Martina [Verfasser], and Johanna [Akademischer Betreuer] Pachmayr. "Sorafenib resistance of hepatocellular carcinoma : antibiotics second-line to Sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption / Martina Meßner ; Betreuer: Johanna Pachmayr." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2020. http://d-nb.info/1216417946/34.
Pełny tekst źródłaPark, Su-In [Verfasser]. "Gemcitabin und Paclitaxel als Second-Line-Therapie beim fortgeschrittenen oder metastasierten Urothel-Karzinom / Su-In Park." Bonn : Universitäts- und Landesbibliothek Bonn, 2012. http://d-nb.info/1043698728/34.
Pełny tekst źródłaKröber, Vinzenz [Verfasser], M. [Akademischer Betreuer] Lommatzsch, K. [Akademischer Betreuer] Jordan, and W. [Akademischer Betreuer] Schütte. "Phase I/II-Studie : Kombinationschemotherapie mit Docetaxel und Pemetrexed in der Second-Line-Therapie bei Patienten mit nichtkleinzelligem Bronchialkarzinom, Stadium IIIB und IV / Vinzenz Kröber. Betreuer: M. Lommatzsch ; K. Jordan ; W. Schütte." Halle, Saale : Universitäts- und Landesbibliothek Sachsen-Anhalt, 2015. http://d-nb.info/1075492904/34.
Pełny tekst źródłaGaspar, Frederico Manuel Gomes Forte Portugal. "Chronic graft-versus-host disease : second line therapy review." Master's thesis, 2017. http://hdl.handle.net/10451/31315.
Pełny tekst źródłaKsiążki na temat "Second-line therapy"
C, Hyde, National Co-ordinating Centre for HTA (Great Britain), and Health Technology Assessment Programme, eds. Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: A technology assessment. Core Research on behalf of the NCCHTA, 2002.
Znajdź pełny tekst źródłaDixon, J. S. Second-line Agents in the Treatment of Rheumatic Diseases (Inflammatory Disease and Therapy). Informa Healthcare, 1991.
Znajdź pełny tekst źródłaCimpean, Anca Maria, Andreea Adriana Jitariu, and Marius Raica. Growth Factors and Their Corresponding Receptors as Targets for Ovarian Cancer Therapy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0011.
Pełny tekst źródłaDougherty, Darin D., Scott L. Rauch, and Michael A. Jenike. Treatments for Obsessive-Compulsive Disorder. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0017.
Pełny tekst źródłaReim, Bernd. Mitomycin C als "Second-line-Therapie" beim fortgeschrittenen metastasierten kolorektalen Karzinom. 1997.
Znajdź pełny tekst źródłaWong, Han Hsi, Basma Greef, and Tim Eisen. Treatment of metastatic renal cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0089.
Pełny tekst źródłaDougherty, Darin D., Scott L. Rauch, and Michael A. Jenike. Pharmacological Treatments for Obsessive Compulsive Disorder. Edited by Gail Steketee. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195376210.013.0061.
Pełny tekst źródłaAsherson, Philip, and Josep Antoni Ramos-Quiroga. Treatment in adult ADHD. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198739258.003.0046.
Pełny tekst źródłaHuntoon, Kristin, and J. Bradley Elder. High-Grade Gliomas. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190696696.003.0001.
Pełny tekst źródłaNiaudet, Patrick, and Alain Meyrier. Minimal change disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0056_update_001.
Pełny tekst źródłaCzęści książek na temat "Second-line therapy"
Lamprecht, Peter, and Paul Klenerman. "Rituximab in Cryoglobulinemic Vasculitis: First- or Second-Line Therapy?" In HCV Infection and Cryoglobulinemia. Springer Milan, 2011. http://dx.doi.org/10.1007/978-88-470-1705-4_39.
Pełny tekst źródłaAxon, A. "Quadruple therapy should be second-line treatment for Helicobacter pylori infection." In Helicobacter pylori. Springer Netherlands, 2000. http://dx.doi.org/10.1007/978-94-011-3927-4_68.
Pełny tekst źródłaCollier, Ann C., and Margot A. Schwartz. "Strategies for Second-Line Antiretroviral Therapy in Adults with HIV Infection." In Antiviral Chemotherapy 5. Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-4743-3_23.
Pełny tekst źródłaRoden, Dylan F., Jennifer M. Johnson, Petr Szturz, Paolo Bossi, and Athanassios Argiris. "New and Promising Targeted Therapies in First and Second-Line Settings." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_18.
Pełny tekst źródłaVannucchi, Alessandro M. "Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy – Second-Line Options." In Myeloproliferative Neoplasms. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-24989-1_11.
Pełny tekst źródłaBettocchi, Carlo, Fabio Castiglione, Omer Onur Cakir, Ugo Falagario, and Anna Ricapito. "Erectile Dysfunction, Surgical and Regenerative Therapy." In Practical Clinical Andrology. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11701-5_5.
Pełny tekst źródłaKulkarni, Harshad R. "PSMA Radioligand Therapy: A Revolution in the Precision Radiomolecular Oncology of Prostate Cancer." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_18.
Pełny tekst źródłaGlass, Bertram, and Marie José Kersten. "Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma." In The EBMT/EHA CAR-T Cell Handbook. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_12.
Pełny tekst źródłaWild, Damian. "Theranostics with Somatostatin Receptor Antagonists." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_35.
Pełny tekst źródłaKramer, D., N. Golz, D. Glaser, and H. Mast. "Treosulfan als Second-Line-Therapie beim fortgeschrittenen Ovarialkarzinom." In Gynäkologie und Geburtshilfe 1990. Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76124-9_111.
Pełny tekst źródłaStreszczenia konferencji na temat "Second-line therapy"
Arentz, Matthew, Patricia Pavlinac, Michael E. Kimerling, David J. Horne, and Judd L. Walson. "Impact Of Antiretroviral Therapy In Patients With Drug Resistant Tuberculosis Requiring Second Line Therapy." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1822.
Pełny tekst źródłaTiwari, Mani, Mahendra Patel, and Khyati Shamaliya. "Peripheral neuropathy in XDR-TB patients on second line anti-tubercular therapy." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2710.
Pełny tekst źródłaDooper, Marten. "No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy." In ESMO Congress 2023, edited by Stefan Rauh. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/0b543d83.
Pełny tekst źródłaSoto, CM Valencia, R. López-Sepúlveda, F. Artime-Rodríguez-Hermida, et al. "4CPS-103 Second-generation tyrosin kinase inhibitors in front-line therapy. comparing responses." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.194.
Pełny tekst źródłaChoudhury, Saswata Paul, Patrick R. LaFontaine, Kalpesh Chatterjee, et al. "703 Shifting landscapes: impact of first-line immuno-oncology therapy on second-line docetaxel treatment in metastatic NSCLC." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0703.
Pełny tekst źródłaHölters, Sebastian, Lothar Bergmann, Viktor Grünwald, et al. "Abstract 901: Plasma proteins characterize second-line therapy response in progressive renal cell carcinoma." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-901.
Pełny tekst źródłaFyles, Fred, Amy Nuttall, Hannah Joplin, Laura Watkins, and Hassan Burhan. "Switching things up: experience of second line anti-interleukin-5 therapy for severe asthma." In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa4100.
Pełny tekst źródłaLiou, Jyh-Ming, Po-Yueh Chen, Chieh-Chang Chen, et al. "IDDF2019-ABS-0126 Levofloxacin sequential therapy versus bismuth quadruple therapy in the second-line and third-line treatment of helicobacter pylori -a multicenter randomized trial." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.159.
Pełny tekst źródłaBackes, Floor, Tirza Areli Calderón Boyle, Jessica Perhanidis, et al. "2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?" In ESGO 2022 Congress. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-esgo.551.
Pełny tekst źródłaHowden, Adam, and Talal Valliani. "P023 The effective use of bezafibrate as a second line therapy for primary biliary cholangitis." In Abstracts of the British Association for the Study of the Liver Annual Meeting, 22–24 November 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2021-basl.32.
Pełny tekst źródłaRaporty organizacyjne na temat "Second-line therapy"
Zhang, Lin-Ming, Xuan-ling Xing, Bing-ran Zhang, et al. Efficacy of Rituximab as Second-Line Therapy for Autoimmune Encephalitis: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.9.0012.
Pełny tekst źródłaGu, Hongmei, Yidan Wang, Guomei Tai, Qiuxing Yang, Jia Liu, and Xiying Shen. Comprehensive curative effect of targeting PD-1 or traditional single-agent chemotherapy in second-line therapy for terminal or metastatic esophageal cancer:A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0019.
Pełny tekst źródłaLiu, Chunyan, Yujia Chen, Rui Rao, Yihui Chai, Yunzhi Chen, and Wen Li. Association of metformin use with asthma development and adverse outcomes: a systematic review and meta-analysis of observational studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.4.0005.
Pełny tekst źródłaShujaa, Asaad Suliman, and Qasem Almulihi. The efficacy and safety of ketamine in treating refractory and super-refractory status epilepticus in pediatric and adult populations, A systemic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.11.0011.
Pełny tekst źródłaSembler, Jose Ignacio, Diether Beuermann, Carlos Elías, and Cheryl Gray. IDB-9: Country Programming. Inter-American Development Bank, 2013. http://dx.doi.org/10.18235/0010515.
Pełny tekst źródła